Document Detail

Hourly blood pressure monitoring after intravenous tissue plasminogen activator for ischemic stroke: does everyone need it?
MedLine Citation:
PMID:  15331797     Owner:  NLM     Status:  MEDLINE    
BACKGROUND AND PURPOSE: Blood pressure (BP) control is considered essential in patients treated with tissue plasminogen activator (tPA) for ischemic stroke, and it is recommended that BP be monitored every 15 minutes to 1 hour for 24 hours in these patients. We postulated that patients whose BP is not initially elevated are unlikely to have elevated BP later and, therefore, may not need prolonged BP monitoring. METHODS: We performed a retrospective chart review of patients treated with intravenous tPA for ischemic stroke over a 3-year period. Patients with incomplete records were excluded. RESULTS: Seventy-nine patients (35 male, age 68.8+/-14.3 years) were studied. Before tPA treatment, 16 patients (20%) had hypertension (systolic BP > or =185 or diastolic BP > or =110 mm Hg). All 16 patients had subsequent hypertension over the next 24 hours. Of the remaining 63, 27 patients (43%) had hypertension (systolic BP > or =180 or diastolic BP > or =105 mm Hg) within the first 6 hours. An additional 4 had minor transient systolic elevations (< or =182 mm Hg) after 6 hours that normalized without treatment. Neurological worsening, seen in 13 patients (17%), was not associated with the presence of hypertension (initial or subsequent). CONCLUSIONS: In patients receiving tPA for stroke, absence of hypertension at presentation does not preclude subsequent increase in blood pressure. However, if blood pressure is not elevated during the first 6 hours, subsequent hypertension over the next 18 hours is unlikely. This study is small and retrospective, and needs to be repeated in a larger prospective cohort. However, our results provide preliminary evidence to suggest that where resources are scarce, these patients may be discharged from the intensive care unit earlier than the recommended 24 hours, provided that they are not at high risk for neurological deterioration.
Venkatesh Aiyagari; Arunodaya Gujjar; Allyson R Zazulia; Michael N Diringer
Related Documents :
10326537 - Echocardiographic assessment of pulmonary hypertension in gaucher's disease.
18710667 - Resistant hypertension.
600967 - Minoxidil in refractory hypertension: benefits, risks.
3709037 - Hypertension and a digoxin-like substance in the plasma of dialysis patients: possible ...
2744157 - Arterial embolism and atrial arrhythmias.
11514087 - Quantitative sensory testing, neurophysiological and psychological examination in patie...
Publication Detail:
Type:  Journal Article; Research Support, U.S. Gov't, P.H.S.     Date:  2004-08-26
Journal Detail:
Title:  Stroke; a journal of cerebral circulation     Volume:  35     ISSN:  1524-4628     ISO Abbreviation:  Stroke     Publication Date:  2004 Oct 
Date Detail:
Created Date:  2004-09-24     Completed Date:  2005-03-22     Revised Date:  2007-11-15    
Medline Journal Info:
Nlm Unique ID:  0235266     Medline TA:  Stroke     Country:  United States    
Other Details:
Languages:  eng     Pagination:  2326-30     Citation Subset:  IM    
Department of Neurology, Washington University School of Medicine, Campus Box 8111, 660 S. Euclid Avenue, St. Louis, MO 63110, USA.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Blood Pressure*
Blood Pressure Determination*
Fibrinolytic Agents / administration & dosage,  therapeutic use*
Infusions, Intravenous
Middle Aged
Retrospective Studies
Stroke / drug therapy*,  physiopathology
Thrombolytic Therapy*
Tissue Plasminogen Activator / administration & dosage,  therapeutic use*
Grant Support
1K23NS044885-01/NS/NINDS NIH HHS; 2 P01 NS035966-06/NS/NINDS NIH HHS
Reg. No./Substance:
0/Fibrinolytic Agents; EC Plasminogen Activator

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Combined anticoagulant-antiplatelet use and major bleeding events in elderly atrial fibrillation pat...
Next Document:  Preliminary report of the effects of complement suppression with pexelizumab on neurocognitive decli...